A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Clinical trial NCT04990258 · UNKNOWN
Trial details
- NCT number
- NCT04990258
- Sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2021-09-06
- Primary completion
- 2024-06-30
- Enrollment
- 444
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.